绥美凯适合什么人用？

Who is it suitable for? Suimeike is a three-in-one compound drug for the treatment of human immunodeficiency virus (HIV) infection. It can not only be used for adult patients, but also has good therapeutic effects on adolescents over 12 years old (weighing more than 40kg).

The dosage of Suimeike for the treatment of adult and adolescent patients is the same. The recommended dosage is one tablet once a day. Regardless of whether they are adults or adolescent patients, if their weight is less than 40kg, they should not take Trimax, because Trimax is a fixed-dose tablet and the dose cannot be reduced, and patients cannot take the medicine at will. Individual formulations of dolutegravir, abacavir, or lamivudine may be used if discontinuation or dose adjustment of one of the active ingredients is necessary and, in these circumstances, physicians should refer to the respective product information for these medicines. 

The following patients are prohibited from using Trimax: 1. Patients with known hypersensitivity to abacavir, dolutegravir, lamivudine or any excipients. 2. It is prohibited to use it in combination with pixicanide and dofetilide. 

Medication for special groups: 1. Elderly patients: Patients are 65 years or older. There are limited data on the use of abacavir, lamivudine and dolutegravir. There is no evidence that elderly patients require different doses than young adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, we need to pay close attention to the use of drugs in elderly patients. 

2. Patients with renal impairment: Patients with creatinine clearance less than 50mL/min are not recommended to take Suimeikai. 

3. Patients with liver damage: One of the main components of Suimeikai is abacavir, which is mainly metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment, therefore the use of Trimax is not recommended unless deemed necessary. For patients with mild hepatic impairment, close monitoring is required, including monitoring of abacavir plasma levels when feasible.

The above is an introduction to the applicable groups, I hope it will be helpful to you.